Copyright
©The Author(s) 2022.
World J Clin Cases. Oct 6, 2022; 10(28): 10066-10076
Published online Oct 6, 2022. doi: 10.12998/wjcc.v10.i28.10066
Published online Oct 6, 2022. doi: 10.12998/wjcc.v10.i28.10066
Table 3 Salvage chemotherapy
Group with TA (n: 15) | Group without TA (n: 15) | ||
2nd line chemotherapy, % | |||
Yes | 4 (26.7) | 8 (53.3) | |
No | 11 (73.3)1 | 7 (46.7) | |
2nd line chemotherapy agents, % | |||
FOLFOX | 3 (75.0) | 0 | |
FOLFIRI | 0 | 6 (75.0) | |
Capecitabine | 1 (25.0) | 2 (25.0) | |
No of chemotherapy line, % | |||
1st line | 11* (73.3) | 7 (46.7) | |
2nd line | 2 (13.3) | 5 (31.3) | |
3rd line | 2 (13.3) | 3 (20.0) |
- Citation: Jang HR, Lee HY, Song SY, Lim KH. Clinical outcomes of targeted therapies in elderly patients aged ≥ 80 years with metastatic colorectal cancer. World J Clin Cases 2022; 10(28): 10066-10076
- URL: https://www.wjgnet.com/2307-8960/full/v10/i28/10066.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i28.10066